Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Novel prostanoid thromboxane A2 agonists

K D Joachim1, U Klar, A Pletsch

  • 1Research Laboratories of Schering AG, Berlin, Germany.

Prostaglandins
|August 1, 1995
PubMed
Summary

Researchers developed novel prostanoid-based agonists targeting the thromboxane A2 (TXA2) receptor. A new compound demonstrated significantly higher potency than the standard TP-receptor agonist U 46619.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo.

Leukemia·2017
Same author

The anti-tumor agent sagopilone shows antiresorptive effects both in vitro and in vivo.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2010
Same author

Forebrain glucocorticoid receptor overexpression increases environmental reactivity and produces a stress-induced spatial discrimination deficit.

Neuroscience·2010
Same author

Characterization of ZK 245186, a novel, selective glucocorticoid receptor agonist for the topical treatment of inflammatory skin diseases.

British journal of pharmacology·2009
Same author

Genetic modifiers of the Kv beta2-null phenotype in mice.

Genes, brain, and behavior·2005
Same author

SEGRAs: a novel class of anti-inflammatory compounds.

Ernst Schering Research Foundation workshop·2002

Area of Science:

  • Medicinal Chemistry
  • Pharmacology
  • Prostanoid Biology

Background:

  • Thromboxane A2 (TXA2) receptors play crucial roles in physiological and pathological processes.
  • Developing selective TXA2 receptor agonists is important for therapeutic interventions.
  • Understanding structure-activity relationships (SAR) is key to designing potent and specific ligands.

Purpose of the Study:

  • To synthesize and characterize novel TXA2 receptor agonists.
  • To investigate the structure-activity relationships of these new compounds.
  • To identify a highly potent TXA2 receptor agonist.

Main Methods:

  • Synthesis of novel compounds based on the prostanoid skeleton.
  • Evaluation of TXA2 receptor agonist activity.
  • Structure-activity relationship analysis.

Main Results:

  • Several novel TXA2 receptor agonists were synthesized and characterized.
  • Compound 33, (5Z,13E), (9R,15R)-9-fluoro-15-hydroxy-16-phenoxy-17,18,19,20-tetranor-5,13-prostadienoic acid, was identified.
  • Compound 33 exhibited 10-fold greater potency compared to the standard TP-receptor agonist U 46619.

Conclusions:

  • Novel prostanoid-based TXA2 receptor agonists were successfully developed.
  • Compound 33 represents a highly potent TP-receptor agonist.
  • These findings provide a basis for further development of TXA2 receptor-targeting therapeutics.

Related Experiment Videos